Jun Gong MD
Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CaliforniaJun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers.
Disclosures
Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.
Recent Contributions to PracticeUpdate:
- Efficacy of Soluble PD-L1 as a Marker for Progressive Disease on Nivolumab
- Efficacy of Axitinib Plus Toripalimab in Metastatic Renal Cell Carcinoma
- Nivolumab Plus Ipilimumab With or Without Live Bacterial Supplementation in mRCC
- Molecular Alterations Across Metastatic Sites Among Patients With RCC
- Neoadjuvant Avelumab/Axitinib for Patients With Localized RCC
- Nivolumab Plus Axitinib for Advanced RCC
- Trastuzumab Deruxtecan Plus Nivolumab Among Patients With HER2-Expressing Urothelial Carcinoma
- Efficacy of the VENUSS Model in Predicting Recurrence After Surgery in Non-Metastatic Papillary RCC
- Prognostic Value of Circulating Tumor Cells and Immune-Inflammatory Cells in RCC
- Prognostic Model Based on Genomic Instability–Related LncRNAs for ccRCC